Clinical trials: Obstructive Pulmonary Diseases
Asthma
Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma
ARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.
- Trial name
- NCT05363670
- Testing
- ARS-1 1 mg, Albuterol MDI, ARS-1 2mg
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- ARS Pharmaceuticals, Inc.
COPD
Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD
Preliminary information from our laboratory indicated that even patients with milder chronic obstructive pulmonary disease (COPD) can have significant physiological derangements which become more pronounced during exercise…
- Trial name
- NCT01491802
- Testing
- LAMA/LABA, LAMA
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- Queen's University
Pulmonary Disease, Chronic Obstructive
Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
Direct comparison studies of the tiotropium HandiHaler® 18 µg and Respimat® 5 µg formulations have been limited to 4-week crossover studies.
- Trial name
- NCT01126437
- Testing
- tiotropium 18 mcg, tiotropium 1.25 mcg (2 actuations/day), tiotropium 2.5 mcg (2 actuations/day)
- Where
- 1,191 sites in United States, Argentina and 49 more
- Volunteers
- 17,183 people
- Sponsor
- Boehringer Ingelheim
Asthma
Specific Use-result Surveillance of Spiriva Respimat in Asthmatics
The safety of Spiriva® 2.5 µg Respimat® 60 puffs (hereinafter referred to as Spiriva® Respimat®) in patients with severe persistent asthma under the real-world use was not confirmed in clinical trials.
- Trial name
- NCT02489981
- Testing
- Spiriva
- Where
- Brazil
- Volunteers
- 359 people
- Sponsor
- Boehringer Ingelheim
Asthma
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study
The primary objective of this study is to evaluate several interventions given to participants with severe asthma. Interventions are administered in a crossover manner with 16-week treatment periods followed by 8 to 16 week…
- Trial name
- NCT04129931
- Testing
- MCT, Clazakizumab, Broncho-Vaxom
- Where
- 29 sites in United States
- Volunteers
- 950 people
- Sponsor
- University of North Carolina, Chapel Hill
Asthma
Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma
The purpose of the study is to evaluate the clinical efficacy of three doses of VR506 delivered via a new dry powder inhaler for the treatment of asthma.
- Trial name
- NCT01472757
- Testing
- VR506
- Where
- 82 sites in United States, Philippines and 3 more
- Volunteers
- 374 people
- Sponsor
- Vectura Limited
Chronic Graft Versus Host Disease
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
To evaluate the safety and efficacy of ibrutinib in combination with prednisone in subjects with newly diagnosed moderate to severe cGVHD.
- Trial name
- iNTEGRATE (NCT02959944)
- Testing
- ibrutinib, Prednisone
- Where
- 102 sites in United States, Australia and 13 more
- Volunteers
- 193 people
- Sponsor
- Pharmacyclics LLC.
Asthma
Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study that aims to assess the efficacy and safety of GSK3511294 (Depemokimab) in participants with severe uncontrolled asthma with an…
- Trial name
- SWIFT-1 (NCT04719832)
- Testing
- GSK3511294 (Depemokimab)
- Where
- 123 sites in United States, Canada and 10 more
- Volunteers
- 395 people
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis, Depressive Symptoms
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
This is a project that will determine whether the use of daily bright light therapy has an effect on depressive symptoms experienced by adult inpatients with CF and COPD.
- Conditions
- Cystic Fibrosis, Depressive Symptoms, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT04921332
- Testing
- Bright Light Therapy (BLT) Lamp
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Erica Osborn
Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD), Laymen Terminology Chronic Bronchitis and Emphysema
A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is the evaluate the safety and tolerability of AZD5069 in patients with Chronic Obstructive Pulmonary Disease
- Trial name
- CIRRUS (NCT01233232)
- Testing
- AZD5069 50mg, AZD5069 80mg
- Where
- 8 sites in Bulgaria, Germany and 2 more
- Volunteers
- 109 people
- Sponsor
- AstraZeneca
Asthma
The Study of Soy Isoflavones in Asthma
The trial is designed to study the effects of soy supplements on asthma control.
- Trial name
- SOYA (NCT01052116)
- Testing
- Soy isoflavone supplement
- Where
- 18 sites in United States
- Volunteers
- 386 people
- Sponsor
- American Lung Association Asthma Clinical Research Centers
Asthma
Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment
This study was a 2-treatment period, randomized, multicenter parallel-group study. The overall purpose of this study was to provide long- term safety data for fevipiprant (QAW039) (Dose 1 and Dose 2), compared with placebo, when…
- Trial name
- NCT03052517
- Testing
- QAW039 150 mg, QAW039 450 mg
- Where
- 347 sites in United States, Argentina and 40 more
- Volunteers
- 2,538 people
- Sponsor
- Novartis Pharmaceuticals
COPD
Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients
This is a multiple dose, randomised, parallel, double blind, double dummy, multicentre and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide/Formoterol fumarate compared with individual…
- Trial name
- AVANT (NCT03022097)
- Testing
- Aclidinium bromide/formoterol Fixed-Dose Combination, Aclidinium bromide, Formoterol Fumarate
- Where
- 74 sites in China, India and 3 more
- Volunteers
- 1,625 people
- Sponsor
- AstraZeneca
Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease
A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease
The overall objective is to investigate the efficacy, safety and tolerability of TEPEZZA® in participants with chronic (inactive) TED (thyroid eye disease). Approximately 57 participants will be enrolled.
- Trial name
- NCT04583735
- Testing
- TEPEZZA
- Where
- 12 sites in United States
- Volunteers
- 62 people
- Sponsor
- Amgen
Chronic Graft-versus-host-disease
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received…
- Trial name
- AGAVE-201 (NCT04710576)
- Testing
- Axatilimab
- Where
- 121 sites in United States, Australia and 14 more
- Volunteers
- 296 people
- Sponsor
- Syndax Pharmaceuticals
Asthma, Atopy
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
There are new, very sensitive methods for detecting bacteria. These methods show that hundreds of millions of microbes (organisms that can only be seen with microscopes), especially bacteria, live in healthy people.
- Trial name
- NCT01537133
- Testing
- fluticasone
- Where
- 9 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Critical Illness, Chronic Disease
Improving Communication About Serious Illness
The purpose of this study is to improve care delivered to patients with serious illness by enhancing communication among patients, families, and clinicians in the outpatient setting.
- Conditions
- Critical Illness, Chronic Disease, Terminal Care, Palliative Care
- Trial name
- ICSI (NCT01933789)
- Testing
- Communication Feedback Form for Patients with Serious Illness
- Where
- 6 sites in United States
- Volunteers
- 817 people
- Sponsor
- University of Washington
Heart Failure, Coronary Artery Disease
COVID-19 Testing in Underserved and Vulnerable Populations
As part of National Institutes of Health Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) program, the goal of the RADxUP study is to develop, test, and evaluate a rapid, scalable capacity building project to…
- Conditions
- Heart Failure, Coronary Artery Disease, Cancer, Chronic Kidney Diseases
- Trial name
- NCT05315908
- Testing
- Community outreach method
- Where
- United States
- Volunteers
- 9,120 people
- Sponsor
- Jesse Nodora
Bronchiolitis
The Bronchiolitis Follow-up Intervention Trial
This study evaluates the value of routine follow-up with a child's pediatrician after hospitalization for bronchiolitis. Parents of half of participants will be instructed to follow-up with the child's pediatrician regardless of…
- Trial name
- BeneFIT (NCT03354325)
- Testing
- Scheduled PCP follow-up, As needed PCP follow-up
- Where
- 4 sites in United States
- Volunteers
- 304 people
- Sponsor
- University of Utah
Asthma
A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers
The primary objective was: to assess the bioequivalence of a single dose (two inhalations) of the test product compared to the reference product, with and without charcoal blockade.
- Trial name
- NCT02237508
- Testing
- Z7200 without oral activated charcoal, Symbicort Turbohaler without oral activated charcoal, Z7200 with oral activated charcoal
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Zambon SpA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.